PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)

This is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjects with unresectable pancreatic adenocarcinoma (uPDAC). These are subjects who are already receiving Gemcitabine for treatment of their disease.

NCT Number	NCT07549958
Lead Sponsor	University of California, Irvine
Conditions	Pancreatic Cancer, Pancreatic Cancer Metastatic
Enrollment	18 participants
Start Date	2026-03-24
Primary Completion	2027-03-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-04